Brief: Palisade Bio Announces Enrollment Of First Patient In Newsoara Phase 3 Clinical Trial Evaluating Lb1148
05/04/2023 13:55
April 5 (Reuters) - Palisade Bio Inc PALI.O :
* PALISADE BIO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN
NEWSOARA
PHASE 3 CLINICAL TRIAL EVALUATING LB1148
* PALISADE BIO INC - TRIAL IS BEING FULLY CONDUCTED AND
FUNDED BY
NEWSOARA
Source text for Eikon: urn:newsml:reuters.com:*:nGNXbfrYT
Further company coverage: PALI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palisade Bio
See all newsPalisade Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Palisade Bio Q2 net loss widens on higher R&D costs
Brief: Palisade Bio Q2 EPS USD -0.05
Palisade Bio Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Palisade Bio Inc - May Offer And Sell Up To $300 Million Of Securities - SEC Filing